Novo provides update on the denecimig Biologics License Application (BLA) in the US
Key takeaways
- Denecimig’s U.S. launch is pushed to early 2027 due to FDA‑required manufacturing site remediation, but Novo says the delay won’t hurt its 2026 earnings.
- BLA submitted September 2025
- Expected decision Q3 2026
- Launch planned H1 2027
What happened
Novo Nordisk said the U.S. Food and Drug Administration is still reviewing its biologics license application for denecimig, a new treatment for haemophilia A. The FDA has not set a new decision date, citing ongoing remediation at Novo’s manufacturing site. The company had submitted the BLA in September 2025 and expected a decision in Q3 2026, but the site inspection has delayed the review. Novo says the remediation work does not affect its other products or its 2026 financial outlook, and it…
Why it matters
The delay means patients and payers will wait longer for a potentially easier‑to‑use haemophilia therapy that could reduce bleeding episodes. For Novo, the extended review could affect cash flow and investor sentiment, even though the company says it will not hit its 2026 earnings guidance. The FDA’s focus on…
Short-term and longer-term
Short-term. In the next few days, watch for any FDA communication that might set a new decision date.
Longer-term. Over the coming months, investors should monitor Novo’s remediation progress and any FDA updates.